glp-1 moa and the kidney: from physiology to pharmacology and outcomes in diabetes Mechanism of action of GLP-1

COMPOUNDED MEDICATION DISCLOSURE: Compounded medications, including compounded semaglutide and tirzepatide, are not FDA-approved drugs and have not been evaluated by the U.S

Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease

(Graphic: Business Wire) Providing access to safe, affordable weight loss solutions is more critical than ever yet many Americans do not have consistent access to these life-changing treatments

The training focuses on foundational concepts in weight management science and evidence-based practice to build knowledge, skills, and competence in pediatric and adult populations